The stock is listed on the Nasdaq Global Select Market

Davis Polk advised the joint book-running managers in connection with the $100 million SEC-registered offering of common stock of CytomX Therapeutics, Inc. The shares are listed on the Nasdaq Global Select Market under the symbol “CTMX.”

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Dove Barbanel, Kathryn Parsons and Ryan Pham. The tax team included counsel Yixuan Long and associates David J. Beer and Hunter P. Shaw. Partner David R. Bauer and associate Gabrielle Mazero provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post